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Effect of Rapamycin on Renal Ischemia Reperfusion Injury
SL Lui1, KW Chan2, R Tsang1, S Yung1, KN Lai1, TM Chan1
Departments of 1Medicine and 2Pathology, The University of Hong Kong,
Queen Mary Hospital, Pokfulam, Hong Kong SAR, China.
Background: The aim of this study was to determine the effect of rapamycin
(Rapa), a relatively new immunosuppressive drug, on renal ischemia reperfusion
injury (IRI) in the mouse. Methods: Renal IRI was induced in male Balb/c
mice by clamping both renal pedicles for 45 minutes. The mice were treated
with either vehicle or Rapa (2 mg/kg/day) by oral gavage, starting 2 days before
the IRI and continued daily until sacrifice. The mice were sacrificed at 1, 3,
and 7 days after the operation. The severity of the IRI was assessed by serum
creatinine levels and renal histology. Proliferation of renal tubular cells was
quantified by immunohistochemical staining for proliferating cell nuclear
antigen (PCNA). Results: One day after the IRI, the serum creatinine levels of
Rapa-treated mice were significantly higher than those of vehicle-treated mice.
Kidney sections from Rapa-treated mice also showed more marked tubular
damage on day 1. The number of PCNA-positive cells in Rapa-treated mice
was significantly lower than that in vehicle-treated mice on days 1 and 3 after
IRI. By day 7 after IRI, there was no significant difference between Rapa- and
vehicle-treated mice in terms of serum creatinine levels, renal histology and
positive PCNA staining.
Serum creatinine (+mol/L) PCNA + nuclei/microscopic field
Vehicle Rapa p Vehicle Rapa p
Day 1 19.8 ( 6.3 26.8 ( 4.8   0.037 13.5 ( 4.9 1.6 ( 0.7 < 0.005
Day 3 16.0 ( 4.0 16.4 ( 2.4 0.72 12.5 ( 7.0 1.1 ( 1.1  0.01
Day 7 14.6 ( 3.0 15.0 ( 2.1 0.47   8.2 ( 3.1 9.3 ( 2.5  0.87
Conclusion: We conclude that Rapa treatment aggravates renal IRI during the
first 1 to 3 days after the insult. This effect might be partly mediated through
inhibition of renal tubular cell regeneration.
Role of PPAR-aAgonist in Diabetic Nephropathy: An In Vitro Study
SCW Tang, JCK Leung, LYY Chan, AWL Tsang, KN Lai
Department of Medicine, University of Hong Kong, Queen Mary Hospital,
Pokfulam, Hong Kong SAR, China.
Background: We have previously shown that advanced glycation end products
(AGEs) in the form of glycated bovine serum albumin (gBSA) incite a
proinflammatory phenotype in proximal tubular epithelial cells (PTECs).
Emerging data suggest that peroxisome proliferator-activated receptor-a (PPAR-
a) agonists may possess anti-inflammatory properties in addition to their insulin-
sensitizing effect in diabetes. Methods: We investigated the intracellular signal
transduction mechanism of gBSA and the impact of the PPAR-a agonist in an
in vitro model of diabetic tubulopathy. Human PTECs, obtained from primary
culture, were exposed to medium alone, or supplemented with BSA (0.5 mg/
mL) or gBSA (0.5 mg/mL) with or without prior addition of rosiglitazone
(0.1–0.5 +M). Results: Exposure to gBSA, but not BSA, significantly
upregulated both mRNA gene and protein expression of IL-8 (p = 0.009 and
p < 0.001 vs BSA, respectively) and sICAM-1 (p = 0.017 and p = 0.05 vs BSA,
respectively), which were dose-dependently attenuated by rosiglitazone. Also
in a dose-dependent fashion, gBSA, but not BSA, caused nuclear translocation
of nuclear factor-kappa B (NF-gB) and activation of mitogen-activated protein
kinases (MAPK) p44 and p42. Both NF-gB and MAPK signals were unaffected
by concurrent treatment with rosiglitazone. Conclusion: AGEs potentiate
tubular inflammation that may be modified by PPAR-a ligation independent of
NF-gB transcriptional activity and MAPK signaling. The anti-inflammatory
effects of PPAR-a agonists in diabetic nephropathy may lie downstream to NF-
gB and MAPK pathways.
The Relationship Between `1-adrenergic Receptor Polymorphisms and
Cardiovascular Disease in Peritoneal Dialysis Patients
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Background: Recent studies show that a common gain-of-function
polymorphism of `1-adrenergic receptor (389 GlyAArg) plays an important
role in the pathogenesis of hypertension and heart failure in patients with normal
renal function. We studied the relationship between `1-adrenergic receptor
polymorphism and cardiovascular disease in peritoneal dialysis (PD) patients.
Methods: We studied 189 new PD patients. The `1-adrenergic receptor
genotype was determined by polymerase chain reaction–restriction fragment
length polymorphism assay. They were then prospectively followed for the
development of cardiovascular events. All-cause mortality and duration of
hospitalization for cardiovascular diseases were also recorded. Results: There
were 95 male cases. The mean age was 56.2 ( 14.8 years. Eighty-six patients
(45.5%) were diabetic; 81 (42.9%) received beta-blocker therapy. Only one
case was homozygous for the mutant CC genotype. The prevalence of GG,
GC, and CC genotypes were 34.9%, 64.6%, and 0.5% respectively. There was
no difference in the prevalence of pre-existing cardiovascular disease between
genotype groups. For GG and GC/CC genotypes, actuarial patient survival was
80.2% and 85.1% at 24 months, respectively (p = 0.53); event-free survival
was 63.6% and 71.5% at 24 months, respectively (p = 0.26); and the duration
of hospitalization was 15.9 ( 3.0 and 16.6 ( 2.3 days per year, respectively
(p = 0.8). The result remained similar when patients with and without beta-
blocker treatment were separately analyzed. Conclusion:  Our study
demonstrates that the `1-adrenergic receptor (389 GlyAArg) polymorphism
is not related to cardiovascular disease in PD patients. Nevertheless, the low
prevalence of the mutant CC genotype in new PD patients suggests either that
this genotype is protective for renal failure or that these patients have high
mortality before they progress to dialysis-dependent renal failure.
Antibody Response to Hepatitis B Vaccine in End-stage Renal
Disease Patients
KM Chow, MC Law, CB Leung, CC Szeto, PKT Li
Department of Medicine and Therapeutics, Prince of Wales Hospital,
The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
Background: This retrospective and comparative study evaluated the
relationship between different factors which may contribute to suboptimal
immunologic response to intramuscular recombinant hepatitis B vaccine in end-
stage renal disease subjects. Methods: From a cohort of 64 dialysis subjects
undergoing primary vaccination with Engerix-B, we determined the predictive
factors that impinged on patients’ response to vaccine, as defined by anti-HBs
level * 10 mIU/L. Dose efficacy was further evaluated by comparing three
historical cohorts vaccinated with the regimens of 20 +g, 40 +g and 80 +g per
dose respectively. Results: We identified 64 end-stage renal disease patients
(mean age, 43 ( 12 years; 81% receiving peritoneal dialysis) who received
primary vaccination from April 1997 to September 2004. Median follow-up
was 6.5 years. They achieved a seroconversion rate of 81%. Older age, diabetes
mellitus, obesity and low Engerix-B dose were risk factors of inadequate anti-
HBs response by univariate analysis. By stepwise logistic regression analysis,
hepatitis B vaccine dose was the only independent predictive factor of impaired
antibody response. An Engerix-B vaccine dose of 20 +g was associated with a
more than tenfold increase in risk of non-response to hepatitis B vaccine (hazards
ratio, 32.2; 95% CI, 3.85–250.0). Immunization with 80 +g of Engerix-B
increased the likelihood of persistent protective antibody (log-rank test, p =
0.014). Immunization with Engerix-B 80 +g is estimated to prevent one extra
end-stage renal disease subject who would lose seroprotective anti-HBs level
at 1 year for every 5.6 patients treated (number needed to treat to benefit,
5.6; 95% CI, 5.4–5.8]). Conclusion: Our results suggest the potential for the
three-dose schedule of recombinant vaccine Engerix-B 80 +g to prolong the
immune response among end-stage renal disease patients.
